Perspective Therapeutics (CATX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 27, 2026, in Chicago, with voting on director elections, auditor ratification, and executive compensation vote frequency.

• Shareholders of record as of April 2, 2026, are eligible to vote, with 114,017,755 shares outstanding.

• Proxy materials are primarily distributed electronically to reduce costs and environmental impact.

• Voting can be done online, by phone, mail, or in person after pre-registration.

Voting matters and shareholder proposals

• Proposal 1: Elect six directors for a one-year term.

• Proposal 2: Ratify WithumSmith+Brown, PC as independent auditor for 2026.

• Proposal 3: Advisory vote on frequency of executive compensation votes, with the board recommending annual votes.

• Board recommends voting “FOR ALL” directors, “FOR” auditor ratification, and “1 YEAR” for say-on-pay frequency.

• Shareholder proposals for the 2027 meeting must be submitted by December 17, 2026.

Board of directors and corporate governance

• Board consists of six members, all nominated for re-election; majority are independent.

• Board leadership structure separates Chairperson and CEO roles for independent oversight.

• Three standing committees: Audit, Compensation, and Nominations, all with independent members.

• Board and committees met regularly, with all members attending at least 75% of meetings.

• Nomination process considers expertise, independence, diversity, and stockholder recommendations.